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Introduction: ROS1 and RET gene fusions were recently discov-
ered in non–small-cell lung cancer (NSCLC) as potential therapeu-
tic targets with small-molecule kinase inhibitors. The conventional 
screening methods of these fusions are time-consuming and require 
samples of high quality and quantity. Here, we describe a novel and 
efficient method by coupling the power of multiplexing polymerase 
chain reaction and the sensitivity of mass spectrometry. 
Methods: The multiplex mass spectrometry platform simultaneously 
tests samples for the expression of nine ROS1 and six RET fusion 
genes. The assay incorporates detection of wild-type exon junctions 
immediately upstream and downstream of the fusion junction to 
exclude false-negative results. To flag false-positives, the system also 
comprises two independent assays for each fusion gene junction. 
Results: The characteristic mass spectrometric peaks of the gene 
fusions were obtained using engineered plasmid constructs. Specific 
assays targeting the wild-type gene exon junctions were validated 
using complimentary DNA from lung tissue of healthy individuals. 
The system was further validated using complimentary DNA derived 
from NSCLC cell lines that express endogenous fusion genes. The 
expressed ROS1-SLC34A2 and CCDC6-RET gene fusions from the 
NSCLC cell lines HCC78 and LC-2/ad, respectively, were accurately 
detected by the novel assay. The assay is extremely sensitive, capable of 
detecting an event in test specimens containing 0.5% positive tumors. 
Conclusion: The novel multiplexed assay is robustly capable of 
detecting 15 different clinically relevant RET and ROS1 fusion 
variants. The benefits of this detection method include exceptionally 
low sample input, high cost efficiency, flexibility, and rapid turnover.
Key Words: Fusion gene, Non–small-cell lung cancer, Mass spec-
trometry, ROS1, RET.
(J Thorac Oncol. 2015;10: 381–386)
The application of high-throughput sequencing methods to investigate the genomic landscape of non–small-cell 
lung cancer (NSCLC) has led to the discovery of greater 
numbers of putative driver oncogene mutations in lung can-
cer.1 Specifically, transcriptome sequencing has enabled the 
discovery of novel ROS1 and RET fusion genes resulting 
from somatic tumor genome rearrangements, and subsequent 
research has verified the oncogenic potential for some.2–8 
Although the prevalence of ROS1 and RET fusion genes 
are approximately 1% to 2% in tumors from an unselected 
population of NSCLC patients,6,9 there is great interest to 
establish robust methods for detection with application to 
research and clinical outcomes. The expression of ROS1 and 
RET fusion genes occurs in the absence of other cancer driver 
mutations, and this mutual exclusivity can be used to enrich 
patient populations for treatment with targeted agents.8 Also, 
NSCLC patients expressing ROS1 or RET fusion genes show 
unique clinicopathologic features that can facilitate thera-
peutic selection (e.g., relatively younger age, never-smoker 
with adenocarcinoma histology).6,9 Finally, at the protein 
level, ROS1 and RET are kinases and small-molecule kinase 
inhibitor drugs shown to target ROS1 (e.g., crizotinib) and 
RET (e.g., cabzantinib, vandetanib, sorafenib, and sunitinib) 
in clinical trials.9,10
Fluorescent in situ hybridization , reverse transcriptase 
polymerase chain reaction (RT-PCR), and immunohistochem-
istry are among the widely used techniques currently applied 
in clinical settings for the detection of fusion genes,6,7,9 and 
each has limitations.11 Recently, Sakai et al 12 promoted a 
multiplexed approach that uses primer-targeted amplification 
and primer extension reactions coupled with matrix-assisted 
laser desorption ionization time-of-flight mass spectrometry 
as a robust method for diagnosis of tumors harboring ALK-
activating rearrangements. The same research group was suc-
cessful in detecting fusion genes when applying the method 
to the analysis of cell-free RNA in serum from lung cancer 
patients.13 This is an attractive method because it requires very 
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little specimen, it is cost-competitive and time-efficient com-
pared with the other approaches, and it was previously demon-
strated to be applicable to formalin-fixed paraffin-embedded 
specimens.14 Based on these advantages, we elected to adapt 
the same test platform for detecting the expression of docu-
mented oncogenic ROS1 and RET fusion genes. Our novel 
multiplexed design strategy represents advancement over 
other mass spectrometry-based tests described in the litera-
ture in that it incorporates controls to indicate false-positive 
and false-negative results. Herein, we describe the multigene, 
multiplexed assay design and validation.
MATERIALS AND METHODS
MassARRAY Procedure Overview 
and Primer Design
The assay tests for the presence of fusion genes in 
specimen-derived mRNA converted to double-stranded 
complimentary DNA (cDNA). Once mRNA is converted, 
the procedure continues with a polymerase chain reaction 
(PCR) amplification step where a short sequence (on aver-
age 100 base pairs) surrounding the fusion gene junction 
or adjacent wild-type exon junction (incorporated as an 
integrated control to verify assay performance) is ampli-
fied. Next, an extension reaction is performed; this adds 
a single base to an extension primer spanning the puta-
tive fusion junction or adjacent wild-type exon junction. 
Finally, matrix-assisted laser desorption time-of-flight 
mass spectrometry analysis is done to detect the expected 
mass spectra of the extension primers. Detailed protocol 
of the assay design and data analysis is provided in the 
Supplemental Digital Content 1 (http://links.lww.com/
JTO/A693). A total of 60 reactions—30 forward and 
reverse reactions at the fusion point and 30 reactions at 
upstream and downstream exon junctions—are multi-
plexed into 12 wells (Fig. 1).
FIGURE 1.  Schematic depicting the major steps of the assay and primers designed to detect the fusion junctions and the 
adjacent wild-type exon boundary junctions. A, Cartoon generalizing multiplexed primer targets. B, List of upstream exon 
junction–targeted primers for the 15 fusion genes and their corresponding masses after the primer extension. C, List of fusion 
junction–targeted extension primers and the respective mass peaks from both forward and reverse directions. D, List of down-
stream exon junction–targeted primers and the respective mass peaks. PCR, polymerase chain reaction.
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Target sequences of the fusion genes (Supplemental Digital 
Content 2, http://links.lww.com/JTO/A694) were obtained from 
published work5,6 and cross-checked with the National Center for 
Biotechnology Information (NCBI) sequences (Homo sapiens 
nucleotide Basic Local Alignment Search Tool [BLAST]). The 
transcript ID of each gene involved in fusions was obtained from 
the Ensemble Genome Browser (http://useast.ensembl.org/index.
html). The Exon Extraction Tool (Sequenom, San Diego, CA) 
was used to annotate exon junctions using the above transcript 
IDs. The immediate upstream and downstream exon junctions 
of the fusion point were annotated manually. Assay Designer 4.0 
software (Sequenom, San Diego, CA) was used to determine the 
product sequences for PCR amplification and extension prim-
ers along with their predicted masses. PCR primers (100 μM, 
25 nmol) and extension primers (200 μM, 100 nmol) were 
ordered from Integrated DNA Technologies (IDT).
Assay Validation
Plasmids comprising synthetic fusion genes—exact 
cDNA surrogates for the endogenously expressed ROS1 
FIGURE 2.  Detection of endogenous expression of the SLC34A2-ROS1 (SL4; R32) fusion gene in complimentary DNA derived 
from the HCC78 cell line. When the fusion gene is present, the characteristic mass spectrometry peak will appear in the analytical 
output of the MassARRAY system (blue arrow) along with the location of depleted extension primer (red arrow). If peaks from other 
reactions not directly related to the reaction lie in the same framed area of the spectrum, they are shown in gray (inactive mode). 
The results for the four reactions relevant to testing for this fusion gene are shown: (A) peak corresponding to the extension primer 
reaction targeting the fusion junction in the forward direction; (B) peak corresponding to the extension primer targeting the fusion 
junction in the reverse direction; (C) peak corresponding to the control extension primer targeting the upstream exon junction; (D) 
peak at predicted mass corresponding to control extension primer reaction targeting the downstream exon junction.
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and RET fusion genes—were used to validate the specificity 
and sensitivity of each assay in multiplex fashion; they were 
acquired from DNA2.0 Inc. (Menlo Park, CA). The cDNA 
sequences of the 15 synthesized fusion genes are given in 
Supplemental Digital Content 3 (http://links.lww.com/JTO/
A695). The copy number of the plasmid cDNA was deter-
mined based on the equation: 6.022E23 [mass of DNA (g)]/
[plasmid size (base pair) × 660 g/mol)]. To validate the func-
tion of control amplification and extension primers target-
ing wild-type gene exon junctions, human lung cDNA (from 
healthy donors) was purchased from Clontech Laboratories, 
CA. To observe mass spectra for wild-type exon junctions, 
0.075 ng/well of healthy cDNA was spiked with plasmid 
DNA. To test for endogenously occurring SLC34A2-ROS1 
(SL4; R32) and the CCDC6-RET fusion genes, cDNA 
from HCC78 and LC-2/ad lung cancer–derived cell lines 
were purchased from Creative Bioarray (New York, NY). 
To check the sensitivity of the assay, the cancer cell cDNA 
was diluted with normal lung cDNA and tested according to 
ratios in Figure 4.
RESULTS
Being that the occurrence of each of these fusion genes 
is rare in patient specimens, we synthesized independent plas-
mid DNA constructs to express each of the 15 fusion genes 
(Supplementary Digital Content 3, http://links.lww.com/JTO/
A695). Using 0.01 pg of each plasmid construct, the assay 
detected all targets from both forward and reverse directions, 
thus validating the specificity and precision of the novel assay. 
The characteristic mass spectrometric peaks for forward and 
FIGURE 3.  Detection of CCDC6-RET (C1; R12) fusion gene expression in LC-2/ad cell line complimentary DNA. The character-
istic mass spectra are shown for: (A) extension primer reaction targeting the fusion junction in the forward direction; (B) exten-
sion primer targeting the fusion junction in the reverse direction; (C) control extension primer targeting the upstream exon 
junction; (D) control extension primer reaction targeting the downstream exon junction.
385Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 2, February 2015 Assay to Analyze ROS1 and RET Gene Fusion
reverse extension primer reactions are given in Supplemental 
Digital Content 4 (http://links.lww.com/JTO/A696).
The detection of wild-type exon junctions was vali-
dated using cDNA derived from lung tissue of healthy indi-
viduals. Our multiplexed assay detected all the targeted exon 
junctions, yielding the predicted mass spectrometric peaks 
(Supplemental Digital Content 5, http://links.lww.com/JTO/
A697). The applicability of the assay was further tested using 
cDNA from two NSCLC cell lines that are known to express 
ROS1 and RET fusion genes, HCC78 and LC-2/ad, respec-
tively.5,15 The ROS1 fusion gene junction comprising ROS1 
exon 32 fused to SLC34A2 exon 4 (R32; SL4) along with 
the upstream and downstream wild-type exon junctions were 
detected in all the designated wells of the HCC78 cell line 
cDNA (Fig. 2). The CCDC6-RET (C1; R12) fusion junction 
together with the upstream and downstream exon junctions 
was detected in all the designated wells in testing the LC-2/ad 
cell line cDNA (Fig. 3).
Finally, the sensitivity of the multiplexed assay was 
tested by analyzing a series of dilutions of HCC78 cell line 
cDNA so that markedly decreased amounts of the ROS1-
SLC34A2 (SL4; R32) fusion gene would be represented in 
each sample. In contrast to making the dilution series in water 
or buffer, a concentration of cell line cDNA harboring the 
fusion gene was spiked into healthy lung cDNA at the ratios 
indicated in Figure 4. The validation was done in duplicate, 
and robust accurate mass spectrometry peaks were attained 
at cancer cell dilutions down to 0.5% (Fig. 4). At a dilution 
of 0.1% cancer cell cDNA (0.002 ng/well), the corresponding 
peak was observed in one run, but not the second, thus bench-
marking the limits of detection sensitivity at 0.5%.
DISCUSSION
Here, we have developed the first mass spectrometry–
based assay to simultaneously detect the expression of known 
oncogenic ROS1 and RET fusion genes in NSCLC. The mul-
tiplexed approach is well suited for screening scarce tumor 
material from patient biopsies. In a recent study to detect 
ALK gene rearrangements, RT-PCR outperformed fluores-
cent in situ hybridization and immunohistochemistry based 
on sensitivity and specificity11; however, the major limitation 
of RT-PCR is that it requires high-quality RNA, largely lim-
iting its applicability to fresh frozen tissues. Our assay uses 
the Sequenom MassARRAY system with the capability to use 
formalin-fixed paraffin-embedded tissues. The novel platform 
has the capacity to simultaneously test 32 samples. Moreover, 
the turnaround time of the assay procedure comes in under 
8 hours. Testing per sample includes four reactions for each 
fusion gene target. This includes the detection of the targeted 
fusion gene sequence in both forward and reverse directions 
and evaluation of the false-negatives by detection of wild-
type exon boundaries upstream and downstream of the fusion 
point. This is the first multiplexed MassARRAY design that 
integrates such controls.
Due to the low frequency of ROS1 and RET gene rear-
rangements in patient specimens, we used synthetic cDNA 
and biospecimens from NSCLC cell lines to test the speci-
ficity and accuracy of each assay in our multiplexed panel. 
To the best of our knowledge, there are only two cell lines 
available, derived from NSCLC reported to express ROS1 
or RET fusion genes—ROS1-SLC34A2 (SL4; R32) in the 
HCC78 cell line and CCDC6-RET in the LC-2/ad cell line—
and our assay detected both the fusions accurately. With 
high-throughput sequencing of greater numbers of NSCLC 
transcriptomes, additional oncogenic variants of the ROS1 
and RET fusion genes may be discovered. If it is the case 
that with further research their identification is verified and 
oncogenic potential characterized, our MassARRAY test can 
be readily expanded to include them. In summary, we have 
provided a robust and flexible screening method that can be 
integrated with other targeted approaches for low-cost, high-
sample throughput analysis.
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